Ethinyl Estradiol

57-63-6 Categories: , ,
  • # LGM Pharma is a Ethinyl Estradiol CAS# 57-63-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ethinyl Estradiol
  • CAS #: 57-63-6
  • Mode of Action:

    Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

  • Pharmacodynamics:

    Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.

  • Metabolism:

    Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.

  • Toxicity:

    Oral, mouse LD50: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.

  • IUPAC: (1S, 10R, 11S, 14R, 15S)-14-ethynyl-15-methyltetracyclo[, {2, 7}.0, {11, 15}]heptadeca-2(7), 3, 5-triene-5, 14-diol
  • ATC: G03CA01
  • PubChem: 5991
  • DrugBank: DB00977 (APRD00691)
  • Formula: C12H16F3N
  • Molecular Mass: 296.4034
  • Synonyms: 17 alpha-Ethinylestradiol 17 alpha-Ethynylestradiol 17 alpha-Ethynyloestradiol 17-ethinyl-3,17-estradiol 17-ethinyl-3,17-oestradiol 17-ethinylestradiol 17alpha-Ethinyl estradiol 17_-ethynylestradiol Ethinyl-Oestranol Ethinylestradiol Ethinylestradiolum [INN-Latin] Ethinylestriol Ethinyloestradiol Ethynyl estradiol Ethynylestradiol Ethynyloestradiol Etinilestradiol [INN-Spanish]
  • SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(O)=C4)[C@@H]1CC[C@@]2(O)C#C
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service